Quarry LP’s Enliven Therapeutics ELVN Stock Holding History

Quarry LP’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-52	Closed	-$1.22K	–	1755
2024 Q2	$1.22K	Buy	+52	New	+$1.09K	﹤0.01%	1684

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Quarry LP's ELVN Position: Q3 2024 in Review

Quarry LP sold out of Enliven Therapeutics (ELVN) in Q3 2024, closing a stake of 52 shares — an estimated $1.22K sold.

Quarry LP first reported a position in ELVN in Q2 2024 and held it in 1 quarter. The position peaked at $1.22K in Q2 2024. 102 funds tracked by Wall St. Rank hold ELVN as of Q3 2024.

Quarry LP reported no remaining Enliven Therapeutics position as of Q3 2024 after selling out during the quarter.
Quarry LP sold 52 Enliven Therapeutics shares in Q3 2024, an estimated $1.22K.
Quarry LP first reported a position in Enliven Therapeutics in Q2 2024 and held it in 1 quarter.
Quarry LP's Enliven Therapeutics position peaked at $1.22K in Q2 2024.
102 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2024.

Based on Quarry LP's 13F filing for Q3 2024, filed 14 Nov 2024.